{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:12:43Z","timestamp":1789647163966,"version":"4.0.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fluoroquinolones (FQ) have shown efficacy against\n                      <jats:italic>Mycobacterium avium<\/jats:italic>\n                      complex (MAC) across experimental settings, in vitro and in vivo. Sitafloxacin (STFX) has demonstrated particularly strong anti-MAC activity, but clinical data on its effectiveness in treating MAC pulmonary disease (MAC-PD) are sparse. This study aimed to evaluate the efficacy of STFX-containing regimens in patients with MAC-PD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 50 patients with MAC-PD who received STFX-containing regimens for \u22656 months at a single center between January 2015 and March 2024. Patients were categorized into four groups: Group 1, STFX-treated without surgery (n = 49); Group 2, STFX started \u22656 months after guideline-based treatment (GBT) began (n = 40); Group 3, poor radiologic response to GBT (n = 38); and Group 4, persistent positive sputum cultures at STFX initiation (n = 19). Primary outcomes assessed at six months included radiologic improvement using the NICE (Nodule, Infiltration, Cavity, Ectasis) score, sputum culture conversion (defined as \u22652 consecutive negative cultures obtained \u22654 weeks apart), and symptom improvement (using the COPD Assessment Test [CAT] score).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Radiologic improvement, symptomatic improvement, and sputum culture conversion were observed in 18.4%, 19.1%, and 20.0% of patients in Group 1; 12.5%, 20.0%, and 12.5% in Group 2; 13.2%, 18.4%, and 13.3% in Group 3; and 5.3%, 15.8%, and 12.5% (2 of 16 evaluable patients) in Group 4, respectively. The two patients who achieved culture conversion had clarithromycin-susceptible strains, non-cavitary disease, and received concomitant ethambutol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>STFX-containing regimens demonstrated modest and overall limited efficacy in patients with MAC-PD, with fewer than 20% achieving radiologic, symptomatic, or microbiological improvement across all groups. STFX may be considered an alternative adjunct when standard therapies are not feasible; however, its overall therapeutic role appears limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-025-04004-1","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:55:29Z","timestamp":1763463329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical efficacy of sitafloxacin-containing regimens for Mycobacterium avium complex pulmonary disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Naohisa","family":"Urabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Tokita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kanokogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rio","family":"Tsunehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"3","key":"4004_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1055\/s-0038-1651491","volume":"39","author":"J Adjemian","year":"2018","unstructured":"Adjemian J, Daniel-Wayman S, Ricotta E, Prevots DR. Epidemiology of nontuberculous mycobacteriosis. Semin Respir Crit Care Med. 2018;39(3):325\u201335.","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"4004_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3201\/eid2206.151086","volume":"22","author":"H Namkoong","year":"2016","unstructured":"Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016;22(6):1116\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"2 Pt 2","key":"4004_CR3","first-page":"S1","volume":"156","author":"American Thoracic Society","year":"1997","unstructured":"American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American thoracic society was approved by the board of Directors, March 1997. Am J Respir Crit Care Med. 1997;156(2 Pt 2):S1\u201325.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4004_CR4","doi-asserted-by":"publisher","first-page":"200535","DOI":"10.1183\/13993003.00535-2020","volume":"56","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr., Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):200535.","journal-title":"Eur Respir J"},{"issue":"5","key":"4004_CR5","doi-asserted-by":"publisher","first-page":"1900189","DOI":"10.1183\/13993003.01636-2018","volume":"53","author":"SM Moon","year":"2019","unstructured":"Moon SM, Jhun BW, Daley CL, Koh WJ. Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. Eur Respir J. 2019;53(5):1900189.","journal-title":"Eur Respir J"},{"issue":"12","key":"4004_CR6","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","volume":"198","author":"DE Griffith","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559\u201369.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"4004_CR7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1513\/AnnalsATS.202008-925OC","volume":"18","author":"KL Winthrop","year":"2021","unstructured":"Winthrop KL, Flume PA, Thomson R, Mange KC, Yuen DW, Ciesielska M, et al. Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: A 12-Month Open-Label extension clinical trial. Ann Am Thorac Soc. 2021;18(7):1147\u201357.","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"4004_CR8","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1128\/AAC.00410-07","volume":"51","author":"Y Kohno","year":"2007","unstructured":"Kohno Y, Ohno H, Miyazaki Y, Higashiyama Y, Yanagihara K, Hirakata Y, et al. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob Agents Chemother. 2007;51(11):4071\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4004_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijantimicag.2010.12.014","volume":"37","author":"C Sano","year":"2011","unstructured":"Sano C, Tatano Y, Shimizu T, Yamabe S, Sato K, Tomioka H. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, Gatifloxacin and Moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents. 2011;37(4):296\u2013301.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"4004_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s10156-011-0303-5","volume":"18","author":"M Fujita","year":"2012","unstructured":"Fujita M, Kajiki A, Tao Y, Miyazaki M, Ouchi H, Harada E, et al. The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease. J Infect Chemother. 2012;18(2):146\u201351.","journal-title":"J Infect Chemother"},{"issue":"7","key":"4004_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/thx.2007.087999","volume":"63","author":"PA Jenkins","year":"2008","unstructured":"Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs Ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008;63(7):627\u201334.","journal-title":"Thorax"},{"issue":"5","key":"4004_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2169\/internalmedicine.53.1277","volume":"53","author":"K Morimoto","year":"2014","unstructured":"Morimoto K, Yoshiyama T, Kurashima A, Sasaki Y, Hoshino Y, Yoshimori K, et al. Nutritional indicators are correlated with the radiological severity score in patients with Mycobacterium avium complex pulmonary disease: a cross-sectional study. Intern Med. 2014;53(5):397\u2013401.","journal-title":"Intern Med"},{"key":"4004_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2466-11-42","volume":"11","author":"PW Jones","year":"2011","unstructured":"Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD assessment test (CAT\u2122) scores. BMC Pulm Med. 2011;11:42.","journal-title":"BMC Pulm Med"},{"issue":"4","key":"4004_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.chest.2019.08.1916","volume":"157","author":"D De la Rosa Carrillo","year":"2020","unstructured":"De la Rosa Carrillo D, Olveira C, Garc\u00eda-Clemente M, Gir\u00f3n-Moreno RM, Nieto-Royo R, Navarro-Rolon A, et al. COPD assessment test in bronchiectasis: minimum clinically important difference and psychometric validation: a prospective study. Chest. 2020;157(4):824\u201333.","journal-title":"Chest"},{"issue":"4","key":"4004_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/jac\/dkq536","volume":"66","author":"T Inagaki","year":"2011","unstructured":"Inagaki T, Yagi T, Ichikawa K, Nakagawa T, Moriyama M, Uchiya K, et al. Evaluation of a rapid detection method of clarithromycin resistance genes in Mycobacterium avium complex isolates. J Antimicrob Chemother. 2011;66(4):722\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4004_CR16","doi-asserted-by":"publisher","first-page":"ofw147","DOI":"10.1093\/ofid\/ofw147","volume":"3","author":"K Fujita","year":"2016","unstructured":"Fujita K, Fujita M, Ito Y, Hirai T, Mio T, Watanabe K, et al. Preliminary evaluation of a sitafloxacin-containing regimen for relapsed or refractory pulmonary Mycobacterium avium complex disease. Open Forum Infect Dis. 2016;3(3):ofw147.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"4004_CR17","doi-asserted-by":"publisher","first-page":"ofz108","DOI":"10.1093\/ofid\/ofz108","volume":"6","author":"T Asakura","year":"2019","unstructured":"Asakura T, Suzuki S, Fukano H, Okamori S, Kusumoto T, Uwamino Y, et al. Sitafloxacin-containing regimen for the treatment of refractory Mycobacterium avium complex lung disease. Open Forum Infect Dis. 2019;6(4):ofz108.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"4004_CR18","doi-asserted-by":"crossref","first-page":"1800946","DOI":"10.1183\/13993003.00170-2018","volume":"51","author":"J van Ingen","year":"2018","unstructured":"van Ingen J, Aksamit T, Andrejak C, B\u00f6ttger EC, Cambau E, Daley CL, et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J. 2018;51(3):1800946.","journal-title":"Eur Respir J"},{"issue":"1","key":"4004_CR19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12890-024-03261-w","volume":"24","author":"N Urabe","year":"2024","unstructured":"Urabe N, Sakamoto S, Tokita N, Yoshida H, Usui Y, Shimizu H, et al. Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation. BMC Pulm Med. 2024;24(1):442.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"4004_CR20","doi-asserted-by":"publisher","first-page":"ofaf118","DOI":"10.1093\/ofid\/ofaf118","volume":"12","author":"Y Kurahara","year":"2025","unstructured":"Kurahara Y, Yoshida S, Osugi A, Tanaka Y, Kobayashi T, Mitsuhashi T, et al. Effects of Amikacin liposome inhalation suspension and Amikacin resistance development in patients with refractory Mycobacterium avium complex pulmonary disease. Open Forum Infect Dis. 2025;12(3):ofaf118.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"4004_CR21","doi-asserted-by":"publisher","first-page":"1901949","DOI":"10.1183\/13993003.01240-2019","volume":"55","author":"H Khadawardi","year":"2020","unstructured":"Khadawardi H, Marras TK, Mehrabi M, Brode SK. Clinical efficacy and safety of fluoroquinolone-containing regimens in patients with Mycobacterium avium complex pulmonary disease. Eur Respir J. 2020;55(4):1901949.","journal-title":"Eur Respir J"},{"issue":"9","key":"4004_CR22","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.3346\/jkms.2020.35.e59","volume":"35","author":"YS Kwon","year":"2020","unstructured":"Kwon YS, Kwon BS, Kim OH, Park YE, Shim TS, Chong YP, et al. Treatment outcomes after discontinuation of ethambutol due to adverse events in Mycobacterium avium complex lung disease. J Korean Med Sci. 2020;35(9):e59.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"4004_CR23","doi-asserted-by":"publisher","first-page":"e0152221","DOI":"10.1128\/aac.01522-21","volume":"66","author":"JH Lee","year":"2022","unstructured":"Lee JH, Park YE, Chong YP, Shim TS, Jo KW. Efficacy of fluoroquinolones as substitutes for ethambutol or Rifampin in the treatment of Mycobacterium avium complex pulmonary disease according to radiologic types. Antimicrob Agents Chemother. 2022;66(2):e0152221.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4004_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","volume":"174","author":"DE Griffith","year":"2006","unstructured":"Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174(8):928\u201334.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"4004_CR25","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/jcm9051315","volume":"9","author":"K Fukushima","year":"2020","unstructured":"Fukushima K, Kitada S, Abe Y, Yamamoto Y, Matsuki T, Kagawa H, et al. Long-term treatment outcome of progressive Mycobacterium avium complex pulmonary disease. J Clin Med. 2020;9(5):1367.","journal-title":"J Clin Med"},{"key":"4004_CR26","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1378\/chest.12-0494","volume":"142","author":"WJ Koh","year":"2012","unstructured":"Koh WJ, Jeong BH, Jeon K, Lee NY, Lee KS, Woo SY, et al. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in Mycobacterium avium complex lung disease. Chest. 2012;142:1482\u20138.","journal-title":"Chest"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-04004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-04004-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-04004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:04:14Z","timestamp":1781615054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-025-04004-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4004"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-04004-1","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Toho University Omori Medical Center (Approval No. M24081). All procedures were conducted in accordance with the principles of the Declaration of Helsinki (2008) for studies involving human subjects. The requirement for informed consent was waived by the Institutional Review Board due to the retrospective study design and use of anonymized patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"532"}}